Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
JMT101 plus osimertinib versus cisplatin plus pemetrexed as first-line treatment for EGFR exon 20 insertion advanced NSCLC
CTR20241252Phase 3Active
- Sponsor
- Shanghai Jinmante Biotechnology Co., Ltd.
- Start
- May 2024
- Modality
- Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 3 trial of becotatug, osimertinib, cisplatin, pemetrexed in non-small cell lung cancer (NSCLC), sponsored by Shanghai Jinmante Biotechnology Co., Ltd.. Started May 2024; status: active.
02
Drugs
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on CTR20241252.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20241252.